AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11979417 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy (ELND)
Number of subjects: 0
Study 11979417 — intervention group
Group type: COMPARATOR
Intervention: Routine extended lymphadenectomy (ELND)
Number of subjects: 0
Study 11979417 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 0
Study 10084094 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngeal/tracheal lignocaine spray immediately before intubation (Group A)
Number of subjects: 30
Study 10084094 — intervention group
Group type: EXPERIMENTAL
Intervention: Orolaryngeal lignocaine spray before induction of anaesthesia (Group B)
Number of subjects: 30
Study 7669712 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN + VMCP
Number of subjects: 256
Study 7669712 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN maintenance
Number of subjects: 256
Study 7669712 — intervention group
Group type: COMPARATOR
Intervention: VMCP
Number of subjects: 256
Study 7669712 — intervention group
Group type: EXPERIMENTAL
Intervention: Global evaluations
Number of subjects: 256
Study 1974675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol 2 mg tablets taken twice daily for 12 weeks
Number of subjects: 140
Study 1974675 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 4 mg tablets taken three times daily for 12 weeks
Number of subjects: 140
Study 6769930 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxythiolin for peritoneal toilet during operation
Number of subjects: 48
Study 6769930 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 30902087 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural sedation and analgesia with propofol in an outpatient setting
Number of subjects: 205
Study 30902087 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia in a clinical setting in the operating theatre
Number of subjects: 205
Study 28448234 — intervention group
Group type: EXPERIMENTAL
Intervention: SPM
Number of subjects: 38
Study 28448234 — intervention group
Group type: EXPERIMENTAL
Intervention: FSL
Number of subjects: 38
Study 28448234 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeSurfer
Number of subjects: 38
Study 28448234 — intervention group
Group type: EXPERIMENTAL
Intervention: SPM's voxel-based morphometry
Number of subjects: 38
Study 25454736 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE) using N-butyl cyanoacrylate (NBCA)
Number of subjects: 26
Study 25454736 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial embolization (TAE) using gelatin sponge particles
Number of subjects: 26
Study 22236044 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss® (group 1)
Number of subjects: 14
Study 22236044 — intervention group
Group type: EXPERIMENTAL
Intervention: Straumann BoneCeramic® (group 2)
Number of subjects: 14
Study 22236044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dehiscence)
Number of subjects: 14
Study 21743091 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient falls prevention education
Number of subjects: 343
Study 21743091 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 343
Study 21743091 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving assistance with activities of daily living
Number of subjects: 343
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement in rating disk degeneration
Number of subjects: 111
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement in rating spondylolisthesis
Number of subjects: 111
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement in rating Modic changes
Number of subjects: 111
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement in rating facet arthropathy
Number of subjects: 111
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement in rating posterior HIZ
Number of subjects: 111
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating spondylolisthesis
Number of subjects: 111
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating disk degeneration
Number of subjects: 111
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating Modic changes
Number of subjects: 111
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating facet arthropathy
Number of subjects: 111
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating posterior HIZ
Number of subjects: 111
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating extent of Modic changes (superior anteroposterior)
Number of subjects: 111
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating extent of Modic changes (inferior anteroposterior)
Number of subjects: 111
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating extent of Modic changes (superior craniocaudal)
Number of subjects: 111
Study 18955509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement in rating extent of Modic changes (inferior craniocaudal)
Number of subjects: 111
Study 17079828 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation therapy
Number of subjects: 60
Study 17079828 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (Control)
Number of subjects: 60
Study 12829943 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions conducted through an academic-community partnership
Number of subjects: 0
Study 10993998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose olanzapine (2.5 to 7.5 mg/day)
Number of subjects: 10
Study 10993998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8792694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 0
Study 8792694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 0
Study 8792694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1401644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked lyophilized fish extracts
Number of subjects: 45
Study 1401644 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned tuna
Number of subjects: 45
Study 1401644 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned salmon
Number of subjects: 45
Study 1401644 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned fish extracts
Number of subjects: 45
Study 1401644 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned tuna and salmon
Number of subjects: 45
Study 2864944 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus dose of vecuronium (10-50 micrograms kg-1)
Number of subjects: 28
Study 2864944 — intervention group
Group type: COMPARATOR
Intervention: Cumulative dose technique
Number of subjects: 28
Study 30143885 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800 mg/day
Number of subjects: 100
Study 30143885 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPA)
Number of subjects: 100
Study 29367439 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimoclomol 200 mg tid
Number of subjects: 38
Study 29367439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 27928077 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric four-drug anti-TB treatment followed 2 weeks later by efavirenz-based ART (ART + TB)
Number of subjects: 43
Study 27928077 — intervention group
Group type: COMPARATOR
Intervention: ART only
Number of subjects: 43
Study 27928077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ART + TB and ART only)
Number of subjects: 43
Study 25230038 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional assessment with the presence of an evaluator
Number of subjects: 20
Study 25230038 — intervention group
Group type: COMPARATOR
Intervention: Filmed assessment without the presence of an evaluator
Number of subjects: 20
Study 22781526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 µg × kg(‐1)× h(‐1)
Number of subjects: 100
Study 22781526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg × kg(‐1)× h(‐1)
Number of subjects: 100
Study 22781526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 µg × kg(‐1)× h(‐1)
Number of subjects: 100
Study 22781526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg × kg(‐1)× h(‐1)
Number of subjects: 100
Study 22781526 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 100
Study 22781526 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (all doses) vs Control
Number of subjects: 100
Study 20234330 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week antibiotic treatment regimen
Number of subjects: 218
Study 20234330 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week antibiotic treatment regimen
Number of subjects: 218
Study 20234330 — intervention group
Group type: COMPARATOR
Intervention: APN (control group)
Number of subjects: 218
Study 19090296 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte Proliferation (LP)
Number of subjects: 100
Study 19090296 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral Neutralization Test (VNT)
Number of subjects: 100
Study 16239860 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 61
Study 16239860 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT) plus parent training
Number of subjects: 61
Study 16239860 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 61
Study 11805685 — intervention group
Group type: EXPERIMENTAL
Intervention: 4PAD
Number of subjects: 10
Study 11805685 — intervention group
Group type: EXPERIMENTAL
Intervention: Bremer
Number of subjects: 10
Study 11805685 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT
Number of subjects: 10
Study 10454704 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance tocolysis
Number of subjects: 1590
Study 10454704 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no maintenance treatment
Number of subjects: 1590
Study 7561123 — intervention group
Group type: EXPERIMENTAL
Intervention: Genentech gp120(IIIB)
Number of subjects: 0
Study 7561123 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroGeneSys gp160(IIIB)
Number of subjects: 0
Study 7561123 — intervention group
Group type: EXPERIMENTAL
Intervention: ImmunoAG gp160(IIIB)
Number of subjects: 0
Study 7561123 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 uninfected gp120/gp160(IIIB) vaccinees
Number of subjects: 0
Study 7561123 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate HIV‐1 recombinant envelope subunit vaccines
Number of subjects: 0
Study 2180792 — intervention group
Group type: EXPERIMENTAL
Intervention: cisapride 0.15 mg/kg intravenously
Number of subjects: 14
Study 2180792 — intervention group
Group type: EXPERIMENTAL
Intervention: cisapride 0.2 mg/kg tid for 4 weeks
Number of subjects: 14
Study 2180792 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 396057 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccines
Number of subjects: 260000
Study 396057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260000
Study 31574504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal side‐to‐side ileo‐colic laparoscopic anastomosis
Number of subjects: 416
Study 31574504 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal anastomosis
Number of subjects: 416
Study 31306043 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day
Number of subjects: 85
Study 28448655 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept, 2.0 mg
Number of subjects: 650
Study 28448655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab, 1.25 mg
Number of subjects: 650
Study 28448655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab, 0.3 mg
Number of subjects: 650
Study 28448655 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept vs Bevacizumab
Number of subjects: 650
Study 28448655 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab vs Bevacizumab
Number of subjects: 650
Study 28448655 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept vs Ranibizumab
Number of subjects: 650
Study 28448655 — intervention group
Group type: COMPARATOR
Intervention: All anti-VEGF treatments
Number of subjects: 650
Study 26276455 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40
Study 26276455 — intervention group
Group type: COMPARATOR
Intervention: Flat occlusal plane appliance (splint)
Number of subjects: 40
Study 26276455 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture and Flat occlusal plane appliance (splint)
Number of subjects: 40
Study 24382705 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Enhanced Video Feedback Engagement (CEVE)
Number of subjects: 19
Study 24382705 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 19
Study 26050277 — intervention group
Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip (PFT) tube
Number of subjects: 58
Study 26050277 — intervention group
Group type: COMPARATOR
Intervention: Standard Mallinckrodt (Covidien) tube
Number of subjects: 58
Study 19242384 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger control training (ACT)
Number of subjects: 26
Study 19242384 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 26
Study 17524243 — intervention group
Group type: COMPARATOR
Intervention: SP (sulfadoxine-pyrimethamine)
Number of subjects: 600
Study 17524243 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus artesunate on day 0 (AS1)
Number of subjects: 600
Study 17524243 — intervention group
Group type: EXPERIMENTAL
Intervention: SP on day 0 and artesunate on each of days 0-2 (AS3)
Number of subjects: 600
Study 15263880 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral CDDZ + 2 mg midazolam by nasal route (Group 1)
Number of subjects: 50
Study 15263880 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (Group 2)
Number of subjects: 50
Study 11171711 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol, 100 microg, two puffs qid for 10 days
Number of subjects: 14
Study 11171711 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalers, two puffs qid for 10 days
Number of subjects: 14
Study 9766832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine topical anesthetic
Number of subjects: 44
Study 9766832 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 44
Study 7850230 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid fluorescent methods for assessment of cholesterol and triglycerides, effective and total concentrations of albumin.
Number of subjects: 0
Study 7850230 — intervention group
Group type: EXPERIMENTAL
Intervention: Total albumin concentration measurement.
Number of subjects: 0
Study 7850230 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of cholesterol and triglycerides over the course of development of acute myocardial infarction.
Number of subjects: 0
Study 2178853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentoxifylline (100 mg)
Number of subjects: 16
Study 2178853 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentoxifylline (400 mg sustained-release tablet)
Number of subjects: 16
Study 2178853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral pentoxifylline
Number of subjects: 16
Study 840561 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 4 (3.0 gm/100 ml, 18:82)
Number of subjects: 106
Study 840561 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 1 (1.5 gm/100 ml, 60:40)
Number of subjects: 106
Study 840561 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 2 (3.0 gm/100 ml, 60:40)
Number of subjects: 106
Study 840561 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 3 (1.5 gm/100 ml, 18:82)
Number of subjects: 106
Study 840561 — intervention group
Group type: COMPARATOR
Intervention: Pooled human milk
Number of subjects: 106
Study 31132094 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP-14
Number of subjects: 5773
Study 31132094 — intervention group
Group type: EXPERIMENTAL
Intervention: 6×BEACOPPesc
Number of subjects: 5773
Study 31132094 — intervention group
Group type: EXPERIMENTAL
Intervention: 8×BEACOPPesc
Number of subjects: 5773
Study 31132094 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 5773
Study 31132094 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraception during treatment
Number of subjects: 5773
Study 31132094 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall thrombotic events
Number of subjects: 5773
Study 31132094 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced HL
Number of subjects: 5773
Study 31132094 — intervention group
Group type: COMPARATOR
Intervention: Early-favorable HL
Number of subjects: 5773
Study 31132094 — intervention group
Group type: COMPARATOR
Intervention: Early-unfavorable HL
Number of subjects: 5773
Study 28968782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin‐piperaquine (DP)
Number of subjects: 0
Study 28968782 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine (SP)
Number of subjects: 0
Study 26210387 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and PerioCol™CG (controlled-release device containing chlorhexidine)
Number of subjects: 40
Study 26210387 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 40
Study 26210387 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and PerioCol™CG
Number of subjects: 40
Study 23638466 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/day
Number of subjects: 858
Study 23638466 — intervention group
Group type: COMPARATOR
Intervention: Glipizide titrated from 5 to 20 mg/day (mean dose 15 mg/day)
Number of subjects: 858
Study 21859655 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients supplementation (n=97)
Number of subjects: 196
Study 21859655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=99)
Number of subjects: 196
Study 19255037 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm children
Number of subjects: 375
Study 19255037 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm children with brain injury
Number of subjects: 375
Study 19255037 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm children without brain injury
Number of subjects: 375
Study 19255037 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe neonatal brain injury
Number of subjects: 375
Study 19255037 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 375
Study 19255037 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal steroids, higher maternal education, and 2-parent family
Number of subjects: 375
Study 19255037 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority status
Number of subjects: 375
Study 19255037 — intervention group
Group type: COMPARATOR
Intervention: Term controls
Number of subjects: 375
Study 17113008 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc Poudrage (TP)
Number of subjects: 109
Study 17113008 — intervention group
Group type: COMPARATOR
Intervention: Talc Slurry (TS)
Number of subjects: 109
Study 15488368 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with decreased safety behaviors under cognitive rationale
Number of subjects: 45
Study 15488368 — intervention group
Group type: COMPARATOR
Intervention: Exposure with decreased safety behaviors under extinction rationale
Number of subjects: 45
Study 15488368 — intervention group
Group type: COMPARATOR
Intervention: Exposure with no change in safety behaviors
Number of subjects: 45
Study 12928995 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 177
Study 12928995 — intervention group
Group type: COMPARATOR
Intervention: Massage
Number of subjects: 177
Study 12928995 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 177
Study 9933852 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 U/kg of r‐HuEPO divided in 4 doses (100 U/kg each, every 4 days)
Number of subjects: 20
Study 9933852 — intervention group
Group type: COMPARATOR
Intervention: 200 U/kg of r‐HuEPO (50 U/kg each, every 4 days)
Number of subjects: 20
Study 7755127 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 16
Study 7755127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2271079 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine cream (PVP-I)
Number of subjects: 0
Study 2271079 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-antibiotic ointment (Neosporin Ointment)
Number of subjects: 0
Study 2271079 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 6775304 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin gel (15 to 30 mg)
Number of subjects: 0
Study 6775304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral slow-release nitroglycerin compound (Lénitral) 2.5 mg
Number of subjects: 0
Study 6775304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral slow-release nitroglycerin compound (Lénitral) 7.5 mg
Number of subjects: 0
Study 12467334 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene cream plus PUVA radiation
Number of subjects: 0
Study 12467334 — intervention group
Group type: COMPARATOR
Intervention: PUVA radiation alone
Number of subjects: 0
Study 30876831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks)
Number of subjects: 550
Study 30342295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical mobilisations
Number of subjects: 40
Study 30342295 — intervention group
Group type: COMPARATOR
Intervention: Placebo (motionless manual contact)
Number of subjects: 40
Study 30342295 — intervention group
Group type: COMPARATOR
Intervention: Cervical mobilisations and Placebo
Number of subjects: 40
Study 26591005 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 70